An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer

A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting

This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC). Data will be collected from patients who have received 1 course of standard systemic chemotherapy, experienced disease progression, and who are receiveingTarceva in a second-line setting. Patients will also be followed through third-line treatment if there is disease progression on Tarceva therapy.

Inclusion Criteria:

• Adult patients ≥ 18 years of age.
• Written informed consent.
• Recurrent or metastatic, Stage III or IV non-small cell lung cancer (NSCLC).
• Measurable disease (Response Evaluation Criteria In Solid Tumors).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Prior course of standard systemic chemotherapy.

Exclusion Criteria:

- Contra-indications to treatment with Tarceva.